PerkinElmer
check quantity

PCSK9 (human) LANCE Ultra TR-FRET Detection Kit, 500 Assay Points

The LANCE® Ultra Human PCSK9 Detection Kit is designed for detection and quantitation of human Proprotein Convertase Subtilisin/Kexin Type 9 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

You successfully added item(s) to your cart

For research use only. Not for use in diagnostic procedures.

Part Number
Unit Size
List Price
Your Price
Quantity
TRF1270C
500 Assay Points
514.00 GBP
more
TRF1270M
10,000 Assay Points
6860.00 GBP
more
Buy Now

Please enter valid quantity

Please login to add favorites

NULL OR EMPTY CART

Detail Information

The LANCE Ultra Human PCSK9 Detection Kit is designed for detection and quantitation of human PCSK9 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

  • No-wash steps, no separation steps
  • TR-FRET technology
  • Sensitive detection
  • High reproducibility
  • Faster time-to-results
  • Easy automation
  • 96-well, 384-well, and 1536-well formats
 

LANCE and LANCE (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.

Human Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) belongs to the proteinase K subfamily of the secretory subtilase family. This glycoprotein contains 692 amino acids, including a signal peptide, a prodomain, and a catalytic domain. Initially synthesized as a soluble 74 kDa precursor protein, it is cleaved into 14 kDa and 60 kDa domains, which remain associated. This protein plays a major regulatory role in cholesterol homeostasis and is highly expressed in the kidney, liver, and intestine. PCSK9 binds to the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. Reduced LDLR levels result in decreased metabolism of low-density lipoprotein, which could lead to hypercholesterolemia. Inhibition of PCSK9 function is currently being explored as a means of lowering cholesterol levels. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia.

Specifications

Assay Target PCSK9
Assay Target Class Protein
Shipping Condition Blue Ice
Therapeutic Area Metabolic
Unit Size 500 Assay Points